Moderna (NASDAQ:MRNA) Stock Price Crosses Below 50-Day Moving Average After Insider Selling

Moderna logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Moderna shares fell below their 50-day moving average, trading as low as $196.52 versus the $205.61 average.
  • President Stephen Hoge disclosed two sales totaling about 78,375 shares for approximately $16.9 million; both transactions were made under pre-arranged Rule 10b5-1 plans.
  • Analysts’ consensus rating is Hold, with an average price target of $120.25. In its latest reported quarter, Moderna beat earnings and revenue expectations, with revenue up 29.2% year over year.
  • MarketBeat previews top five stocks to own in December.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s share price passed below its 50-day moving average during trading on Wednesday after an insider sold shares in the company. The stock has a 50-day moving average of $205.61 and traded as low as $196.52. Moderna shares last traded at $196.79, with a volume of 6,954,950 shares.

Specifically, President Stephen Hoge sold 39,160 shares of Moderna stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $219.66, for a total transaction of $8,601,885.60. Following the transaction, the president owned 1,673,858 shares of the company's stock, valued at $367,679,648.28. The trade was a 2.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,215 shares of the company's stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $211.61, for a total value of $8,298,286.15. Following the completion of the transaction, the president owned 1,311,095 shares in the company, valued at $277,440,812.95. This represents a 2.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

A number of brokerages have issued reports on MRNA. Royal Bank Of Canada reissued a "sector perform" rating and set a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Rothschild & Co Redburn downgraded shares of Moderna from a "neutral" rating to a "sell" rating and upped their price target for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Evercore increased their price objective on Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. Sanford C. Bernstein reissued a "market perform" rating on shares of Moderna in a research report on Friday, September 25th. Finally, Deutsche Bank assumed coverage on Moderna in a research note on Friday, August 28th. They issued a "hold" rating and a $125.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $120.25.

Get Our Latest Report on Moderna

Key Stories Impacting Moderna

Investors following MRNA have been watching these stories:

  • Positive Sentiment: Moderna’s Phase 3 adjuvant melanoma results were described as clinical proof of concept, strengthening the outlook for its immuno-oncology program, according to Morgan Stanley. Read article
  • Neutral Sentiment: Morgan Stanley raised its price target from $95 to $200 but kept an “equal weight” rating, signaling a more constructive target without a bullish recommendation. Read article
  • Negative Sentiment: Recent coverage says the shares have extended a losing streak after a major year-to-date rally, raising concerns about momentum and whether expectations already reflect a recovery. Read article Read analysis

Moderna Stock Performance

The stock has a market cap of $79.63 billion, a P/E ratio of -27.72 and a beta of 1.16. The firm has a 50 day moving average of $205.61 and a two-hundred day moving average of $98.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion during the quarter, compared to analysts' expectations of $890.25 million. During the same quarter last year, the company earned ($0.51) earnings per share. The firm's revenue was up 29.2% on a year-over-year basis. On average, research analysts predict that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRNA. BlackRock Inc. bought a new stake in Moderna in the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new position in Moderna during the 2nd quarter worth about $564,272,000. Aberdeen Group plc raised its stake in shares of Moderna by 6,931.1% during the 3rd quarter. Aberdeen Group plc now owns 1,054,306 shares of the company's stock worth $203,028,000 after acquiring an additional 1,039,311 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock worth $172,384,000 after acquiring an additional 103,977 shares in the last quarter. Finally, Merck & Co. Inc. purchased a new position in shares of Moderna in the second quarter worth about $161,642,545. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines